28 recruiting, 17 completed, 10 active not recruiting, 7 not yet recruiting. 13 Not applicable, 13 Phase 2, 6 Phase 3, 4 Phase 1, 1 Early Phase 1.
Follow Natera, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2026-12-01 | 2026-08-04 |
| TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma Tafasitamab, Polatuzumab vedotin, Glofitamab - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 2 | Not yet recruiting | Brown University | 30 | 2026-11-01 | 2026-09-01 |
| Signatera Assessment in Early-Stage Endometrial Cancer Signatera Genome ultra-sensitive ctDNA blood test - Endometrial Cancer | Not applicable | Not yet recruiting | Natera, Inc. | 1010 | 2026-10-01 | 2026-06-17 |
| The Surveillance Nonoperative Watch & Wait (SNOWW) Rectal Cancer Trial. Cancer of the Rectum | Withdrawn | University of Colorado, Denver | 2026-10-01 | 2026-06-09 | ||
| Rising ctDNA to Tailor Endocrine Therapy Switch in Patients With ER+/HER2- Metastatic Breast Cancer. Tumor assessment, Completion of Quality-of-life questionnaires, ECG - Metastatic Invasive Breast Cancer | Phase 3 | Not yet recruiting | UNICANCER | 370 | 2026-09-25 | 2026-07-21 |
| Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer Signatera Genome ultra-sensitive ctDNA blood test - Gastric-Esophageal Cancer | Not applicable | Not yet recruiting | Natera, Inc. | 1000 | 2026-09-01 | 2026-05-04 |
| ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma Pembrolizumab, Non-investigational, involved site radiotherapy (ISRT), Gemcitabine - Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma | Phase 2 | Recruiting | Michael Spinner, MD | 38 | 2026-08-18 | 2026-10-20 |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder Cancer (SCORE-NMIBC) Non-Muscle Invasive Bladder Cancer, NMIBC | Recruiting | Natera, Inc. | 400 | 2026-07-27 | 2026-08-13 | |
| Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) Non-Hodgkin Lymphoma, T-Cell Lymphoma | Recruiting | Natera, Inc. | 200 | 2026-07-27 | 2026-08-06 | |
| Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test Capecitabine, Oxaliplatin, Folfirinox - Colorectal Cancer | Phase 3 | Active not recruiting | UNICANCER | 2450 | 2026-07-20 | 2026-07-22 |
| AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas Tislelizumab, Leucovorin, Oxaliplatin - Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | American Association for Cancer Research | 242 | 2026-07-20 | 2026-10-05 |
| Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT) Prospera Immunosuppression Optimization - Kidney Transplant, Immunosuppresion | Not applicable | Not yet recruiting | Natera, Inc. | 750 | 2026-07-01 | 2026-07-22 |
| Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors Whole blood for ctDNA - Germ Cell Cancer Metastatic | Not applicable | Recruiting | Indiana University | 130 | 2026-06-03 | 2026-06-15 |
| Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer ctDNA-Guided Treatment Strategy - Breast Neoplasms, Carcinoma, Ductal, Breast | Not applicable | Recruiting | Natera, Inc. | 725 | 2026-05-08 | 2026-09-23 |
| Feasibility Trial of Combination of Obstetrical Carrier Screening and Hereditary Cancer Screening Natera empower comprehensive hereditary cancer panel, Obstetrical carrier screening - Hereditary Cancer Syndrome | Recruiting | Columbia University | 1000 | 2026-02-12 | 2026-10-21 | |
| Circulating Tumor DNA Response In Urothelial Cancer Pembrolizumab & Enfortumab Vedotin (PEV), Pembrolizumab - Urothelial Carcinoma | Phase 2 | Recruiting | University of Oklahoma | 30 | 2026-01-19 | 2026-02-02 |
| Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA Blood draw to measure the levels of dd-cf DNA - Cardiac Allograft Vasculopathy, Endothelial Dysfunction | Withdrawn | Yale University | 2025-12-01 | 2025-11-06 | ||
| ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness blood sample for Signatera (TM) test, biopsy for Ki-67 assessment, FFPE tumor sample for Signatera (TM) test (archived) - Early and Locally Advanced Breast Cancer | Not applicable | Recruiting | Austrian Breast & Colorectal Cancer Study Group | 350 | 2025-08-13 | 2026-08-19 |
| Sample Collection for Ongoing Research and Product Evaluation Study Breast Cancer, Lung Cancer | Recruiting | Natera, Inc. | 9600 | 2025-07-21 | 2026-01-15 | |
| Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC) Colo-rectal Cancer | Recruiting | Natera, Inc. | 25000 | 2025-05-30 | 2025-12-12 |
Showing 20 of 77. Sign in to see all of them.
Breast Neoplasms (9) · Down Syndrome (9) · Trisomy 13 Syndrome (9) · Trisomy 18 Syndrome (9) · Colonic Neoplasms (8) · Colorectal Neoplasms (8) · Turner Syndrome (7) · Rectal Neoplasms (6) · Sex Chromosome Aberrations (6) · Melanoma (5) · Carcinoma, Non-Small-Cell Lung (4) · Lymphoma, Large B-Cell, Diffuse (3) · Neoplasm, Residual (3) · Pancreatic Neoplasms (3) · Rejection, Psychology (3)
Blood Specimen Collection (5) · Biopsy (3) · Capecitabine (3) · Oxaliplatin (3) · pembrolizumab (3) · Fluorouracil (2) · Folfox protocol (2) · Leucovorin (2) · atezolizumab (2) · tislelizumab (2) · Anastrozole (1) · Bevacizumab (1) · Cyclophosphamide (1) · Drug Combinations (1) · Fertilization in Vitro (1)
United States (61) · Canada (7) · Spain (6) · Australia (5) · Czechia (5) · United Kingdom (5) · France (4) · Ireland (4) · Italy (4) · Germany (3) · Poland (3) · South Korea (3) · Sweden (3) · Austria (2) · Belgium (2)
Matthew Rabinowitz, PhD (4) · Michael Olymbios, MD (4) · Josef Stehlik, MD (3) · Palak Shah, MD (3) · Peer Dar, MD (2) · Philip F Halloran, MD PhD (2) · Adam ElNaggar, MD (1) · Adam Olszewski (1) · Adanma Ayanambakkam, MD (1) · Adel Kardosh, M.D.,Ph.D. (1) · Adham Jurdi, MD (1) · Alexey Aleshin, MD (1) · Alexey Aleshin, MD, MBA (1) · Angel Rodriguez, MD (1)
PMID 36508644, PMID 38538559, PMID 10417280, PMID 12820840, PMID 16814942, PMID 20375405, PMID 21310373, PMID 21519036, PMID 22005709, PMID 22281937, PMID 22464072, PMID 22617594, PMID 22742782, PMID 23215555, PMID 23613152, PMID 23712453, PMID 24135152, PMID 24388429, PMID 24785862, PMID 25004354, PMID 25111587, PMID 25479548, PMID 25834952, PMID 26984449, PMID 28079901, PMID 30094065, PMID 31070691, PMID 32632268, PMID 33634869, PMID 34561256, PMID 35033576, PMID 35058354, PMID 35085538, PMID 35636789, PMID 35765145, PMID 36190186, PMID 36965866, PMID 37082935, PMID 37310258, PMID 37794564, PMID 38150492, PMID 38595232, PMID 40232852, PMID 40854490, PMID 40980666, PMID 41124204, PMID 41241034, PMID 41492943, PMID 41563380, PMID 41698326
2023 (1), 2025 (1), R44HD062114 (1), U10CA180868 (1)